Weight Gain Impacts 25(OH)D Response in Pregnancy

This article originally appeared here.
Share this content:
Weight Gain Impacts 25(OH)D Response in Pregnancy
Weight Gain Impacts 25(OH)D Response in Pregnancy

TUESDAY, Nov. 1, 2016 (HealthDay News) -- Among pregnant women taking cholecalciferol, factors have been identified that impact serum 25-hydroxyvitamin D (25[OH]D) response, including weight gain and season of delivery, according to research published online Oct. 27 in the Journal of Clinical Endocrinology & Metabolism.

Rebecca J. Moon, B.Sc., B.M., from the University of Southampton in the United Kingdom, and colleagues conducted a within-randomization group analysis of participants in the Maternal Vitamin D Osteoporosis Study. Eight hundred twenty-nine pregnant women were enrolled (422 placebo, 407 cholecalciferol). Maternal anthropometry, health, and lifestyle were assessed at 14 and 34 weeks of gestation and 25(OH)D was measured.

The researchers found that women randomized to vitamin D had higher 25(OH)D at 34 weeks of gestation compared to women randomized to placebo (mean, 67.7 versus 43.1 nmol/L; P < 0.001). Among women randomized to cholecalciferol, there were independent associations for lower 25(OH)D at 34 weeks of gestation with higher pregnancy weight gain from 14 to 34 weeks of gestation, lower compliance with study medication, lower early pregnancy 25(OH)D, and delivery in the winter versus the summer.

"Future studies should aim to determine appropriate doses to enable consistent repletion of 25(OH)D during pregnancy," the authors write

Several authors disclosed financial ties to pharmaceutical and medical device companies, including Merck, which provided the Vigantoletten supplement.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »